These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29854169)

  • 1. Mechanism-based Pharmacovigilance over the Life Sciences Linked Open Data Cloud.
    Kamdar MR; Musen MA
    AMIA Annu Symp Proc; 2017; 2017():1014-1023. PubMed ID: 29854169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects.
    Kontsioti E; Maskell S; Anderson I; Pirmohamed M
    Clin Pharmacol Ther; 2024 Jul; 116(1):165-176. PubMed ID: 38590106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation.
    Lee S; Lee JH; Kim GJ; Kim JY; Shin H; Ko I; Choe S; Kim JH
    J Med Internet Res; 2022 Oct; 24(10):e35464. PubMed ID: 36201386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database.
    Yavne Y; Amar Shamir R; Shapiro M; Shepshelovich D
    Expert Opin Drug Saf; 2023; 22(6):463-468. PubMed ID: 36683587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
    Shin H; Lee S
    BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis.
    Lavertu A; Hamamsy T; Altman RB
    J Med Internet Res; 2021 Oct; 23(10):e27714. PubMed ID: 34673524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.
    Pham M; Cheng F; Ramachandran K
    Drug Saf; 2019 Jun; 42(6):743-750. PubMed ID: 30762164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions.
    Kontsioti E; Maskell S; Pirmohamed M
    Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):832-844. PubMed ID: 36916014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.
    Liu R; Zhang P
    BMC Med Inform Decis Mak; 2019 Dec; 19(1):279. PubMed ID: 31849321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach.
    Wang L; Shendre A; Chiang CW; Cao W; Ning X; Zhang P; Zhang P; Li L
    Br J Clin Pharmacol; 2022 Feb; 88(4):1471-1481. PubMed ID: 33543792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.
    Li Y; Jimeno Yepes A; Xiao C
    Drug Saf; 2020 Sep; 43(9):893-903. PubMed ID: 32385840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mining heterogeneous networks with topological features constructed from patient-contributed content for pharmacovigilance.
    Yang CC; Yang H
    Artif Intell Med; 2018 Aug; 90():42-52. PubMed ID: 30093253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.